10 Most Profitable Biotech Stocks to Invest in Now

5. United Therapeutics Corporation (NASDAQ:UTHR)

TTM Net Income: $1.21 billion

Number of Hedge Fund Holders: 43

United Therapeutics Corporation (NASDAQ:UTHR) is one of the most profitable biotech stocks to invest in now. In a report released on July 23, Roanna Ruiz from Leerink Partners maintained a Buy rating on United Therapeutics Corporation (NASDAQ:UTHR) with a price target of $408.00, basing the rating on the company’s growth and stability.

Ruiz expects United Therapeutics Corporation (NASDAQ:UTHR) to undergo meaningful growth in its Tyvaso franchise, especially in the PH-ILD market, which may support the base business.

He also considers the upcoming Phase 3 TETON-2 IPF data, which is anticipated in the second half of 2025, to be a critical catalyst that may considerably boost United Therapeutics Corporation (NASDAQ:UTHR) stock in the case of positive results.

In addition, United Therapeutics Corporation (NASDAQ:UTHR) has strong relationships with key physicians, strategic positioning with payers, and an established commercial presence, factors that Ruiz considers helpful in mitigating competitive pressures.

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and commercializes products for patients with chronic and life-threatening conditions. Its product portfolio includes Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin.